Atypical Hemolytic Uremic Syndrome (aHUS) Latest Advances

Hockman A, Anuskiewicz S, Brennan E, et al. Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Blood Adv. 2025;9(23):6096-6107.

Journal: Blood advances

Published: June 12, 2026

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Journal: Internal medicine (Tokyo, Japan)

Published: June 10, 2026

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome With Kidney Recovery Despite Delayed Initiation of Complement Blockade.

Journal: Cureus

Published: April 30, 2026

Therapeutic Plasma Exchange in a 15-kg Child With Atypical Hemolytic Uremic Syndrome: A Case Report.

Journal: Cureus

Published: April 20, 2026

Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: April 15, 2026

Functional Characterization of a Novel Intronic Complement Factor I Variant in Factor I Deficiency and Atypical Hemolytic Uremic Syndrome.

Journal: Kidney international reports

Published: March 26, 2026

Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review.

Journal: Frontiers in pharmacology

Published: March 19, 2026

Advances in analytical methods for regulatory complement proteins in research and clinical applications.

Journal: Talanta

Published: March 16, 2026

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: March 16, 2026

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Journal: Frontiers in immunology

Published: March 11, 2026

Hematologic disorders in pregnancy: the role of the complement system.

Journal: Expert review of hematology

Published: March 05, 2026

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Journal: Health technology assessment (Winchester, England)

Published: March 03, 2026

Atypical Hemolytic Uremic Syndrome (aHUS) Latest Advances

Find the Latest Research About Atypical Hemolytic Uremic Syndrome (aHUS)

Hockman A, Anuskiewicz S, Brennan E, et al. Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Blood Adv. 2025;9(23):6096-6107.

Hockman A, Anuskiewicz S, Brennan E, et al. Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Blood Adv. 2025;9(23):6096-6107.

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome With Kidney Recovery Despite Delayed Initiation of Complement Blockade.

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome With Kidney Recovery Despite Delayed Initiation of Complement Blockade.

Therapeutic Plasma Exchange in a 15-kg Child With Atypical Hemolytic Uremic Syndrome: A Case Report.

Therapeutic Plasma Exchange in a 15-kg Child With Atypical Hemolytic Uremic Syndrome: A Case Report.

Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children

Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children

Functional Characterization of a Novel Intronic Complement Factor I Variant in Factor I Deficiency and Atypical Hemolytic Uremic Syndrome.

Functional Characterization of a Novel Intronic Complement Factor I Variant in Factor I Deficiency and Atypical Hemolytic Uremic Syndrome.

Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review.

Therapeutic advances in eculizumab for atypical hemolytic uremic syndrome: a narrative review.

Advances in analytical methods for regulatory complement proteins in research and clinical applications.

Advances in analytical methods for regulatory complement proteins in research and clinical applications.

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Clinical efficacy and safety of eculizumab in pediatric atypical hemolytic uremic syndrome

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Hematologic disorders in pregnancy: the role of the complement system.

Hematologic disorders in pregnancy: the role of the complement system.

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.